• 13.01.2020 – 11:43

  COMPASS Pathways

  COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression

  London (ots/PRNewswire) - COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office. The patent covers the use of COMPASS's ...

  more

• 09.01.2020 – 13:00

  Debiopharm International SA

  Novadiscovery raises series A financing to scale its in silico clinical trial platform - Debiopharm leads the round with EUR 5 million

  Lausanne (ots) - - Novadiscovery pioneers the use of in silico clinical trials to predict drug efficacy and optimize clinical development, an approach meeting the strong expectations from pharmaceutical companies for faster and more efficient development, and benefiting from increased endorsement from health ...

  more

• 08.01.2020 – 14:59

  Ottobock

  

  Cascade Orthopedic Supply Announces Investment by Ottobock North America

  more

• 08.01.2020 – 14:00

  Debiopharm International SA

  Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

  MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...

  more

• 06.01.2020 – 15:23

  Senzer Limited

  Senzer's Pharmaceutical Inhaler Selected for Major Cannabinoid Patient Registry

  London (ots/PRNewswire) - Senzer's pharmaceutical respiratory device will be used in Europe's first and biggest national medical cannabis registry, Project TWENTY21, in which an expected 20,000 patients will be enrolled by the end of 2021 creating the largest body of evidence for the efficacy of medical cannabis. Drug Science, the leading independent scientific body on ...

  more

• 06.01.2020 – 10:00

  Kyowa Kirin International PLC

  Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

  Tokyo (ots/PRNewswire) - Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) ...

  more

• 18.12.2019 – 14:07

  Grünenthal Group

  Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

  Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

  more

• 18.12.2019 – 09:00

  Daiichi Sankyo Europe GmbH

  Large Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities

  Munich (ots/PRNewswire) - · Results published in the European Heart Journal - Cardiovascular Pharmacotherapy, showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial[1] · Study reports LIXIANA outcomes from one of the largest observational studies in mainly Caucasian AF ...

  more

• 16.12.2019 – 12:00

  Sysmex Inostics GmbH

  Sysmex Inostics announces first results of tissue-independent liquid biopsy for early stage breast cancer mutation characterization and monitoring using ultra-sensitive SafeSEQ technology

  Hamburg, Germany and Baltimore, Maryland (ots) - New data presented by Dr. Ben Ho Park, Professor of Medicine and Director of Precision Oncology at Vanderbilt University and colleagues at the recent San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas demonstrated a potential utility for monitoring ...

  more

• 12.12.2019 – 09:00

  COMPASS Pathways

  COMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers

  London (ots/PRNewswire) - COMP360 (psilocybin) was well tolerated in healthy volunteers and results support further investigation of simultaneous 1:1 therapeutic administration design COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to ...

  more

• 10.12.2019 – 11:17

  Grünenthal Group

  

  Jan Adams appointed Chief Scientific Officer

  more

• 10.12.2019 – 01:45

  UCB Pharma

  UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

  Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...

  more

• 09.12.2019 – 17:02

  Cannamedical Pharma GmbH

  Cannamedical® provides pharmacists with CBD-kit for the formulation of medical, GMP-compliant CBD-oil

  Cologne (ots) - Cannamedical® Pharma GmbH, one of the leading cannabis distributors and supplier of one of the best-known medical Cannabis brands in Germany and the European Union, is now offering a GMP-certified kit for the formulation of pharmaceutical CBD-oils. With this formulation kit, Cannamedical® enables ...

  more

• 06.12.2019 – 03:00

  Fresenius Kabi Deutschland GmbH

  

  2

  Medical experts highlight nutrition survey data during 20th PENSA Congress 2019 in Hong Kong

  more

• 04.12.2019 – 12:22

  APR Applied Pharma Research s.a.

  FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa

  Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-named APR-TD011 for treatment of ...

  more

• 04.12.2019 – 09:01

  ForaCare Suisse AG

  ForaCare Suisse AG Launches "Lab in the Pocket" Technology

  ST. GALLEN, Switzerland (ots) - Innovative FORA 6 GTel Capability Provides 6 Tests with Single Device, SIM Direct-to-Telehealth Connectivity ForaCare Suisse AG announced the launch of its FORA 6 GTel multi-functional monitoring device with its new "Lab in the Pocket" technology (available on the GTel model and FORA 6 Series products). The innovative 6-in-1 monitoring technology provides seamless 3G/4G data transmission of ...

  more

• 20.11.2019 – 08:01

  Merck KGaA

  Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations

  Darmstadt, Germany (ots/PRNewswire) - - Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in ...

  more

• 19.11.2019 – 13:38

  Gerresheimer AG

  New Focus in Project Portfolio of Gerresheimer Subsidiary Sensile Medical

  Dusseldorf, Germany (ots/PRNewswire) - - SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment - Sanofi terminates development project for micro pumps for patients with diabetes - Further projects with pharma customers for various therapy areas for the micro pump started Sensile Medical, a subsidiary of Gerresheimer AG, has signed ...

  more

• 19.11.2019 – 12:00

  Gerresheimer AG

  New focus in project portfolio of Gerresheimer subsidiary Sensile Medical

  Duesseldorf (ots) - - SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment - Sanofi terminates development project for micro pumps for patients with diabetes - Further projects with pharma customers for various therapy areas for the micro pump started Sensile Medical, a subsidiary of Gerresheimer AG, has signed a contract with the ...

  more

• 19.11.2019 – 11:18

  Personal MedSystems GmbH

  

  2

  CardioSecur introduces 3D-ECG for virtual trials at Clinical Trials Europe

  more

  One document

• 18.11.2019 – 14:00

  Fresenius Kabi Deutschland GmbH

  Fresenius Kabi starts United for Clinical Nutrition initiative in Europe with first-of-its-kind clinical study assessing critically ill patients in 11 European countries

  Bad Homburg (ots) - The first patients are about to be enrolled in the EuroPN survey, a clinical study that will assess the nutritional balance and focus on functional outcomes of critically ill patients in about 100 hospitals across 11 European countries. The survey is an important scientific project by United for ...

  more

• 08.11.2019 – 10:00

  Fresenius Kabi Deutschland GmbH

  Omega-3 fatty-acid enriched parenteral nutrition improves patient outcomes

  BAD HOMBURG, GERMANY (ots) - A new systematic literature review and meta-analysis1 confirms and extends previous results that omega-3 (omega-3) fatty-acid enriched parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients. Including a total of 49 randomized controlled trials (RCTs), this literature review provides the most ...

  more

• 08.11.2019 – 09:00

  Debiopharm International SA

  Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program

  Lausanne (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today it has been awarded the 2nd phase funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to continue the development of its antibiotic program Debio 1453, leading to a novel ...

  more

• 06.11.2019 – 14:39

  Stada Arzneimittel

  

  Press release: Alvotech and STADA agree on strategic biosimilar partnership

  more

  One document

• 06.11.2019 – 09:30

  Hitachi Medical Systems Europe Holding AG

  

  2

  Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI

  more

• 05.11.2019 – 13:24

  Ottobock

  

  2

  Ottobock collaborates with Vigo to enhance care for patients in Belgium and Poland

  more

• 05.11.2019 – 12:58

  LOG Pharma

  LOG Pharma Packaging to Launch ActiveGuard® CONNECT(TM) at CPhI Worldwide 2019

  Frankfurt, Germany (ots/PRNewswire) - Smart packaging solution boosts medication adherence by 23% LOG Pharma Packaging announced today that it will launch its innovative patent pending line of ActiveGuard® CONNECT(TM) smart packaging solutions at CPhI Worldwide 2019 in Frankfurt, Germany from 5-7 November. ActiveGuard® CONNECT(TM) was developed in cooperation with ...

  more